Amydis, Inc.
Amydis is the leader in developing a new class of diagnostic compounds that enable digital detection and monitoring of human disease-related molecular biomarkers through standard ocular imaging cameras.
Funding history
About Amydis, Inc.
How much funding has Amydis, Inc. raised?
Amydis, Inc. has raised $3.0M in total funding. The most recent round was Series A.
Where is Amydis, Inc. headquartered?
Amydis, Inc. is headquartered in Los Angeles, CA.
What does Amydis, Inc. do?
Amydis is the leader in developing a new class of diagnostic compounds that enable digital detection and monitoring of human disease-related molecular biomarkers through standard ocular imaging cameras.
What problem does Amydis, Inc. solve?
The site frames disease diagnosis (for brain, eye, and heart diseases) as often 'a race against time.'
What's Amydis, Inc.'s solution?
Amydis develops ocular tracers that enable digital detection and monitoring of disease-related molecular biomarkers using standard ocular imaging cameras, aiming to accelerate diagnosis and improve testing of new therapeutics.
What makes Amydis, Inc. different?
The site claims to be 'the leader' in this ocular biomarker detection approach and cites NIH grant funding (including $2.5M) to develop a diagnostic eye test for ALS via the biomarker TDP-43.
What makes Amydis, Inc. notable?
Amydis, founded by Dr. Stella Sarraf in 2013, develops an eye-based diagnostic test for neurodegenerative diseases and counts the Michael J. Fox Foundation among its funders.
Leadership
❝ Cite this page
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated August 26, 2026.